REGENERON'S ANTIBODY COCKTAIL REGN-EB3 (INMAZEB®) IS FIRST FDA-APPROVED TREATMENT FOR EBOLA (ZAIRE EBOLAVIRUS)
https://investor.regeneron.com/index.php/news-releases/news-release-details/regenerons-antibody-cocktail-regn-eb3-inmazebr-first-fdaTARRYTOWN, N.Y., October 14, 2020 – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that the U.S. Food and Drug Administration (FDA) approved Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn) for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including newborns of mothers who have tested positive for the infection.
“We are incredibly proud that the FDA has approved Inmazeb, which is also known as REGN-EB3. This is the first time the FDA has approved a treatment specifically for Ebola, which has caused a number of deadly outbreaks,†said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron. ...
